Celularity Inc (CELU)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.68-8.20%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CELU
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-10.5) + peer(0.2*3.1) + term(0.0) → -3.05% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On May 9, 2025, Celularity Inc. issued a press release announcing operating and financial results for the year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this report, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of th…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition On November 7, 2024, Celularity Inc., or Celularity, issued a press release providing an update on expected net sales for the ten-month period ending October 31, 2024. This preliminary information reflects Celularity’s current expectations regarding financial performance but does not constitute finalized results for either the third quarter ended September 30, 2024, or the fourth quarter ending December 31, 2024. A copy of the press release is fur…
Results of Operations and Financial Condition Although it has not yet finalized its financial results for the three months and six months ended June 30, 2024, Celularity Inc., or Celularity, announced in an October 22, 2024 letter to shareholders (the “Letter to Shareholders”) by Celularity’s Chief Executive Officer, Robert J. Hariri, MD, PhD, that it expects to report revenues from its biomaterial products in excess of $24 million of net revenue for the six months ending June 30, 2024. Bioma…
Results of Operations and Financial Condition Although it has not yet finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2023, nor for the first quarter ended March 31, 2024, Celularity Inc. (“Celularity”) announced on May 21, 2024, that it expects to report that it had approximately $12.1 million of net revenue for the quarter ended December 31, 2023, and expects to have approximately $14.8 million of net revenue for the quarter ended March 31, 202…